Ascletis Pharma Inc. expects to record (i) a total revenue ranging from RMB 46.0 million to RMB 47.0million for the six months ended June 30, 2023, representing an increase of approximately 20.4% to 23.0% from approximately RMB 38.2 million for the six months ended June 30, 2022; and (ii) a net loss attributable to the owners of the Company ranging from RMB 14.0 million to RMB 22.0 million for the six months ended June 30, 2023, representing a decrease of approximately 84.1% to 75.0% as compared to that for the six months ended June 30, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.36 HKD | -2.86% | -2.86% | -6.85% |
03/04 | Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus | MT |
03/04 | Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.85% | 181M | |
-2.35% | 89.33B | |
+3.29% | 41.19B | |
-16.02% | 31.87B | |
+53.42% | 24.52B | |
-14.79% | 15.68B | |
-6.52% | 12.34B | |
-39.65% | 12.23B | |
+6.22% | 8.83B | |
-6.43% | 8.28B |
- Stock Market
- Equities
- 1672 Stock
- News Ascletis Pharma Inc.
- Ascletis Pharma Inc. Provides Earnings Guidance for the Six Months Ended June 30, 2023